Acadia Pharmaceuticals Inc
ACAD
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.42B
Close$
$-9.81
149.2% downside
Current Fair Value
149.2% downsideOvervalued by 149.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.42 Billion |
|---|---|
| Enterprise Value | $3.11 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.32 |
| Beta | 0.86 |
| Outstanding Shares | 171,603,000 |
Return
| Return on Equity | 29.12% |
|---|---|
| Return on Assets | 21.83% |
| Return on Invested Capital | 6.27% |
Valuation & Multiples
| P/E Ratio | 8.87 |
|---|---|
| PEG | 48.91 |
| Price to Sales | 3.33 |
| Price to Book Ratio | 2.85 |
| Enterprise Value to Revenue | 2.73 |
| Enterprise Value to EBIT | 35.83 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$295.83 M
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$0.21
Average shareholder expectationRevenue Estimate
$332.06 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0008▲ 31.99% |
|---|---|
| Total Calls | 246,100▼ 54.60% |
| Total Puts | 246,300▼ 33.27% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 99.01%▲ 2.35% |
|---|---|
| Total Invested | $4.30B▲ 17.15% |
| Investors Holding | 365▲ 7.00% |
ESG Score
No data
About Acadia Pharmaceuticals Inc
CEO: Uli Hacksell